Show simple item record

dc.contributor.authorBandeiras, Cátia
dc.contributor.authorHwa, Albert J.
dc.contributor.authorCabral, Joaquim M. S.
dc.contributor.authorFerreira, Frederico Castelo
dc.contributor.authorFinkelstein, Stan Neil
dc.contributor.authorGabbay, Robert A.
dc.date.accessioned2020-11-18T16:54:00Z
dc.date.available2020-11-18T16:54:00Z
dc.date.issued2019-08
dc.identifier.issn1534-4827
dc.identifier.issn1539-0829
dc.identifier.urihttps://hdl.handle.net/1721.1/128519
dc.description.abstractPurpose of Review: Type 1 diabetes impacts 1.3 million people in the USA with a total direct lifetime medical cost of $133.7 billion. Management requires a mix of daily exogenous insulin administration and frequent glucose monitoring. Decision-making by the individual can be burdensome. Recent Findings: Beta-cell replacement, which involves devices protecting cells from autoimmunity and allo-rejection, aims at restoring physiological glucose regulation and improving clinical outcomes in patients. Given the significant burden of T1D in the healthcare systems, cost-effectiveness analyses can drive innovation and policymaking in the area. Summary: This review presents the health economics analyses performed for donor-derived islet transplantation and the possible outcomes of stem cell-derived beta cells. Long-term cost-effectiveness of islet transplantation depends on the engraftment of these transplants, and the expenses and thresholds assumed by healthcare systems in different countries. Early health technology assessment analyses for stem cell-derived beta-cell replacement suggest manufacturing optimization is necessary to reduce upfront costs.en_US
dc.publisherSpringer Science and Business Media LLCen_US
dc.relation.isversionofhttps://doi.org/10.1007/s11892-019-1203-9en_US
dc.rightsArticle is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.en_US
dc.sourceSpringer USen_US
dc.titleEconomics of Beta-Cell Replacement Therapyen_US
dc.typeArticleen_US
dc.identifier.citationBandeiras, Cátia et al. "Economics of Beta-Cell Replacement Therapy." Current Diabetes Reports 19, 9 (August 2019): 75 © 2019 Springer Science Business Media, LLCen_US
dc.contributor.departmentMassachusetts Institute of Technology. Institute for Data, Systems, and Societyen_US
dc.relation.journalCurrent Diabetes Reportsen_US
dc.eprint.versionAuthor's final manuscripten_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dc.date.updated2020-09-24T21:44:50Z
dc.language.rfc3066en
dc.rights.holderSpringer Science+Business Media, LLC, part of Springer Nature
dspace.embargo.termsY
dspace.date.submission2020-09-24T21:44:50Z
mit.journal.volume19en_US
mit.journal.issue9en_US
mit.licensePUBLISHER_POLICY


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record